Oppenheimer Reiterates Outperform on Allogene Therapeutics, Maintains $28 Price Target
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Mark Breidenbach has reiterated his 'Outperform' rating on Allogene Therapeutics (NASDAQ:ALLO), maintaining a price target of $28.
August 04, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst has reiterated an 'Outperform' rating on Allogene Therapeutics, maintaining a price target of $28.
The reiteration of the 'Outperform' rating by Oppenheimer indicates a positive outlook for Allogene Therapeutics. The maintained price target of $28 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100